Chemistry:NNC 01-0687
 | |
| Clinical data | |
|---|---|
| Other names | ADX-10061; CEE 03-310; CEE-310; NNC 01-687; NNC-687; NO-687 |
| Drug class | Dopamine D1-like receptor antagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H20N2O4 |
| Molar mass | 340.379 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NNC 01-0687 (also known as ADX-10061, CEE-03-310, or NNC-687) is a selective dopamine D1-like receptor antagonist of the benzazepine group which was under development as an experimental antipsychotic for the treatment of schizophrenia but was never marketed.[1][2][3] Its development for schizophrenia was discontinued due to lack of effectiveness in clinical trials.[2][4]
Subsequently, NNC 01-0687 was developed under the code name ADX-10061 for treatment of substance dependence and was studied for smoking cessation, alcohol dependence, and cocaine dependence.[3] It was also developed for treatment of sleep disorders.[1] However, development for all of these indications was also discontinued, by 2007, and the drug was never marketed for any use.[1]
The drug has been found to increase slow wave sleep (deep sleep) in humans.[5]
NNC 01-0687 was first described in the scientific literature by 1992.[6]
See also
- Substituted 3-benzazepine
- Berupipam (NNC 22-0010)
- Ecopipam (SCH-39166)
- Odapipam (NNC 01-0756)
- SCH-23390
References
- ↑ 1.0 1.1 1.2 "ADX 10061". AdisInsight. Springer Nature Switzerland AG. 3 October 2007. https://adisinsight.springer.com/drugs/800001476.
- ↑ 2.0 2.1 "Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents". Molecular Psychiatry 17 (12): 1206–1227. December 2012. doi:10.1038/mp.2012.47. PMID 22584864.
- ↑ 3.0 3.1 "Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction". Current Psychiatry Reviews (Bentham Science Publishers Ltd.) 1 (1): 45–67. 1 January 2005. doi:10.2174/1573400052953538. ISSN 1573-4005.
- ↑ "Current strategies for the development of novel antipsychotic drugs". Mini Reviews in Medicinal Chemistry 3 (3): 239–251. May 2003. doi:10.2174/1389557033488169. PMID 12570839.
- ↑ "Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687)". J Psychiatr Res 37 (4): 305–312. 2003. doi:10.1016/s0022-3956(03)00007-4. PMID 12765853.
- ↑ "Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography". Journal of Chromatography 577 (2): 366–370. June 1992. doi:10.1016/0378-4347(92)80261-n. PMID 1301070.
 |  |
